Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours

NCT01134250 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT01134250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01134250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours
Lead sponsor
Philogen S.p.A.
Phase
Phase 1/2
Overall status
Completed
Start date
August 6, 2008
Completion date
April 7, 2014
Enrollment
48 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastatic melanoma, non-small cell lung cancer (nsclc), solid tumor